Clinical and economic outcomes of pharmacist-managed antimicrobial prophylaxis in surgical patients

American Journal of Health-System Pharmacy

Volumn 64, Issue 18, 2007, Pages 1935-1942

  Bond, C A ^a,b   Raehl, Cynthia L ^b  

^a Department of Pharmacy ^*  (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Antiinfective agents; Costs; Data collection; Health benefit programs; Hospitals; Infections; Mortality; Outcomes; Pharmaceutical services; Pharmacists, hospital; Pharmacy, institutional, hospital; Surgery

Indexed keywords

ARTICLE; LENGTH OF STAY; MEDICARE; MORTALITY; PHARMACIST; PRIORITY JOURNAL; SURGICAL INFECTION; SURGICAL PATIENT; TREATMENT OUTCOME; ANTIBIOTIC PROPHYLAXIS; ECONOMICS; HOSPITAL PHARMACY; HUMAN; OUTCOME ASSESSMENT;

ANTIBIOTIC PROPHYLAXIS; HUMANS; MEDICARE; OUTCOME ASSESSMENT (HEALTH CARE); PHARMACISTS; PHARMACY SERVICE, HOSPITAL; SURGICAL WOUND INFECTION;

EID: 34548730839     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060631     Document Type: Article

References (73)

1. Auerbach AD. Prevention of surgical site infections. In: Shojania KG, Duncan BW, McDonald KM et al., eds. Making health care safer: a critical analysis of patient safety practices. www.ahrq.gov/clinic/ptsafety/pdf/ptsafety. pdf (accessed 2006 Oct 18).
2. Wallace WC, Cinat M, Gornick WB et al. Nosocomial infections in surgical intensive care unit: a difference between trauma and surgical patients. Am Surg. 1999; 65:987-90.
3. Delgado-Rodriguez M, Sillero-Arenas M, Medina-Cuadros M et al. Nosocomial infections in surgical patients: comparison of two measures of intrinsic patient risk. Infect Control Hosp Epidemiol. 1997; 18:19-23.
4. Horan TC, Culver DH, Gaynes RP et al. Nosocomial infections in surgical patients in the United States, January 1986-June 1992. National Nosocomial Infections Surveillance (NNIS) System. Infect Control Hosp Epidemiol. 1993; 14:73-80.
5. Mangram AJ, Horan TC, Pearson ML et al. Guideline for prevention of surgical site infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control. 1999; 27:97-132.
6. Wong ES. Surgical site infection. In: Mayhall DG, ed. Hospital epidemiology and infection control. 2nd ed. Philadelphia: Lippincott, Williams & Wilkins; 1999:189-210.
7. Kirkland KB, Briggs JP, Trivette SL et al. The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs. Infect Control Hosp Epidemiol. 1999; 20:725-30.
8. Miles AA, Miles EM, Burke J. The value and duration of defence reactions of skin to the primary lodgement of bacteria. Br J Exp Pathol. 1957; 38:79-96.
9. Burke JF. The effective period of preventive antibiotic action in experimental incisions and dermal lesions. Surgery. 1961; 50:161-8.
10. Polk HC Jr, Lopez-Mayor JF. Postoperative wound infection: a prospective study of determinant factors and prevention. Surgery. 1969; 66:97-103.
11. Stone HH, Hooper CA, Kolb LD et al. Antibiotic prophylaxis in gastric, biliary, and colonic surgery. Ann Surg. 1976; 184: 443-52.
12. Polk HC Jr, Trachtenberg L, Finn MP. Antibiotic activity in surgical incisions: the basis for prophylaxis in selected operations. JAMA. 1980; 244:1353-4.
13. DiPiro JT, Vallner JJ, Bowden TA Jr et al. Intraoperative serum and tissue activity of cefazolin and cefoxitin. Arch Surg. 1985; 120:829-32.
14. Classen DC, Evans RS, Pestotnik SL et al. The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. N Engl J Med. 1992; 326:281-6.
15. Page CP, Bohnen JM, Fletcher JR et al. Antimicrobial prophylaxis for surgical wounds: guidelines for clinical care. Arch Surg. 1993; 128:79-88. [Erratum, Arch Surg. 1993; 128:410.]
16. Dellinger EP, Cross PA, Barrett TL et al. Quality standard for antimicrobial prophylaxis in surgical procedures: Infectious Diseases Society of America. Clin Infect Dis. 1994; 18:422-7.
17. American Society of Health-System Pharmacists. ASHP therapeutic guidelines on antimicrobial prophylaxis in surgery. Am J Health-Syst Pharm. 1999; 56:1839-88.
18. Mangram AJ, Horan TC, Pearson ML et al. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1999; 20:250-78.
19. ACOG Committee on Practice Bulletins. Antibiotic prophylaxis for gynecologic procedures. ACOG Practice Bulletin 23. Washington, DC: American College of Obstetricians and Gynecologists; 2001.
20. Gilbert DN, Moellering RC, Sande MA. The Sanford guide to antimicrobial therapy. 33rd ed. Hyde Park, VT: Antimicrobial Therapy; 2003:127-33
21. Silver A, Eichorn A, Kral J et al. Timeliness and use of antibiotic prophylaxis in selected inpatient surgery procedures. Am J Surg. 1996; 171:548-52.
22. Matuschka PR, Cheadie WG, Burke JD et al. A new standard of care: administration of preoperative antibiotics in the operating room. Am Surg. 1997; 63:500-3.
23. Gorecki P, Schein M, Rucinski JC et al. Antibiotic administration in patients undergoing common surgical procedures in a community teaching hospital: the chaos continues. World J Surg. 1999; 23:429-33.
24. Trick WE, Scheckler WE, Tokars JI et al. Modifiable risk factors associated with deep sternal site infection after coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2000; 119:108-14.
25. Bratzler DW, Houck PM, Richards C et al. Use of antimicrobial prophylaxis for major surgery: baseline results from the National Surgical Infection Prevention Project. Arch Surg. 2005; 140:174-82.
26. McGlynn EA, Asch SM, Adams J et al. The quality of health care delivered to adults in the United States. N Engl J Med. 2003; 348:2635-45.
27. Board on Health Care Services. Enhancing federal health care quality programs. Washington, DC: National Academies Press; 2003:1.
28. Committee on Quality of Health Care in America. Crossing the quality chasm: a new health system for the 21st century. Washington, DC: National Academy Press; 2001:1.
29. Expanded Modified Medicare Provider Analysis and Review (MEDPAR-Hospital [National] FY 1998). Baltimore, MD: Centers for Medicare and Medicaid Services. Tape cartridges.
30. Bond CA, Raehl CL, Pitterle ME et al. Health care professional staffing, hospital characteristics, and hospital mortality rates. Pharmacotherapy. 1999; 19:130-8.
31. Bond CA, Raehl CL, Franke T. Clinical pharmacy services and hospital mortality rates. Pharmacotherapy. 1999; 19:556-64.
32. Bond CA, Raehl CL, Franke T. Clinical pharmacy services, pharmacist staffing, and drug costs in United States hospitals. Pharmacotherapy. 1999; 19:1354-62.
33. Bond CA, Raehl CL, Franke T. Clinical pharmacy services, pharmacy staffing, and the total cost of care in United States hospitals. Pharmacotherapy. 2000; 20:609-21.
34. Bond CA, Raehl CL, Franke T. Interrelationships among mortality rates, drug costs, total cost of care, and length of stay in United States hospitals: summary and recommendations for clinical pharmacy services and staffing. Pharmacotherapy. 2001; 21:129-41.
35. Bond CA, Raehl CL, Franke T. Clinical pharmacy services, hospital pharmacy staffing, and medication errors in United States hospitals. Pharmacotherapy. 2002; 22:134-47.
36. Bond CA, Raehl CL, Franke T. Medication errors in United States hospitals. Pharmacotherapy. 2001; 21:1023-36.
37. Schumock GT, Butler MG, Meek PD et al. Evidence of the economic benefit of clinical pharmacy services: 1996-2000. Pharmacotherapy. 2003; 23:113-32.
38. Leape LL, Cullen DJ, Clapp MD et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 1999; 282:267-70. [Erratum, JAMA. 2000; 283:1293.]
39. Schumock GT, Meek PD, Ploetz PA et al. Economic evaluation of clinical pharmacy services; 1988-1995. Pharmacotherapy. 1996; 16:1188-208.
40. Bond CA, Monson R. Sustained improvement in drug documentation, compliance, and disease control: a four-year analysis of an ambulatory care model. Arch Intern Med. 1984; 144:1159-62.
41. Monson R, Bond CA, Schuna A. Role of the clinical pharmacist in improving outpatient drug therapy. Arch Intern Med. 1981; 141:1441-4.
42. Gattis WA, Hasselblad V, Whellan DJ et al. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. Arch Intern Med. 1999; 159:1939-45.
43. Kaushal R, Bates DW, Landrigan C et al. Medication errors and adverse drug events in pediatric inpatients. JAMA. 2001; 285:2114-20.
44. Clapham CE, Hepler CE, Reinders TP et al. Economic consequences of two drug-use control systems in a teaching hospital. Am J Hosp Pharm. 1988; 45:2329-40.
45. Jenkins MH, Bond CA. The impact of clinical pharmacists on psychiatric patients. Pharmacotherapy. 1996; 16:708-14.
46. McKenney JM, Wasserman AJ. Effect of advanced pharmaceutical services on the incidence of adverse drug reactions. Am J Hosp Pharm. 1979; 36:1691-7.
47. Bond CA, Raehl CL. Pharmacist-provided anticoagulation management in United States hospitals: death rates, length of stay, Medicare charges, bleeding complications, and transfusions. Pharmacotherapy. 2004; 24:953-63.
48. Bond CA, Raehl CL. Clinical and economic outcomes of pharmacist-managed aminoglycoside or vancomycin therapy. Am J Health-Syst Pharm. 2005; 62:1596-605.
49. Bond CA, Raehl CL, Franke T. Clinical pharmacy services, hospital pharmacy staffing, and hospital mortality rates. Pharmacotherapy. 2007; 27:481-93.
50. Bond CA, Raehl CL. Clinical pharmacy services, pharmacy staffing, and adverse drug reactions in United States hospitals. Pharmacotherapy. 2006; 26:735-47.
51. Raehl CL, Bond CA. 1998 National Clinical Pharmacy Services Study. Pharmacotherapy. 2000; 20:436-60.
52. Raehl CL, Bond CA, Pitterle ME. 1995 National Clinical Pharmacy Services Study. Pharmacotherapy. 1998; 18:302-26.
53. Raehl CL, Bond CA, Pitterle ME. Hospital pharmacy services in the Great Lakes region. Am J Hosp Pharm. 1990; 49:1283-303.
54. Raehl CL, Bond CA, Pitterle ME. Pharmaceutical services in U.S. hospitals in 1989. Am J Hosp Pharm. 1992; 49:323-46.
55. Bond CA, Raehl CL, Pitterle ME. 1992 National Clinical Pharmacy Services Study. Pharmacotherapy. 1994; 14:282-304.
56. American Hospital Association abridged guide to the healthcare field. Chicago: American Hospital Association; 1998. Diskettes.
57. Unicor Medical, Inc. ICD-9CM easy coder. Montgomery, AL: Unicor Medical, Inc. 1998.
58. Rosko MD, Broyles RW. The economics of health care: a reference handbook. Westport, CT: Greenwood; 1998.
59. Prospective Payment Assessment Commission. Medicare prospective payment and the American health care system. Washington, DC: Health Care Financing Administration; 1990. HCFA publication no. HE 22.21/3:398.
60. Centers for Medicare and Medicaid Services. Surgical infection prevention project description. www.medqic.org/sip (accessed 2006 Oct 2).
61. Keely JL, for the American College of Physicians-American Society of Internal Medicine. Pharmacist scope of practice. Ann Intern Med. 2002; 136:79-85.
62. American Society of Health-System Pharmacists. The 2015 Health-System Pharmacy Initiative, Objective 1.3. www. ashp.org/2015/Obj1.cfm? (accessed 2006 Nov 2).
63. Hammond RW, Schwartz AH, Campbell MJ et al. Collaborative drug therapy management by pharmacists - 2003. Pharmacotherapy. 2003; 23:1210-25.
64. Bond CA, Raehl CL. Clinical and economic outcomes of pharmacist-managed antiepileptic drug therapy. Pharmacotherapy. 2006; 26:1369-78.
65. Dubois RW, Brooks RH, Rodgers WH. Adjusted hospital death rates: a potential screen for quality of medical care. Am J Public Health. 1987; 77:1162-7.
66. Krakauer H, Bailey RC, Skellan KJ et al. Evaluation of the HCFA model for the analysis of mortality following hospitalization. Health Serv Res. 1992; 27:317-35.
67. Hartz AJ, Krakauer H, Kuhn EM et al. Hospital characteristics and mortality rates. N Engl J Med. 1989; 321:1720-5.
68. Keeler EB, Rubenstein LV, Kahn KL et al. Hospital characteristics and quality of care. JAMA. 1992; 268:1709-14.
69. Pfeffer J, Sutton RI. Evidence-based management. Harv Bus Rev. 2006; 84(1): 62-74, 133.
70. American College of Surgeons National Surgical Quality Improvement Program. History of the ACS NSQIP. https://acsnsqip.org/main/about_history.asp (accessed 2006 Nov 12).
71. Centers for Disease Control and Prevention. The National Nosocomial Infections Surveillance (NNIS) system. www.cdc. gov/ncidod/dhqp/nnis.html (accessed 2006 Nov 12).
72. Bond CA, Raehl CL, Patry R. Evidence-based core clinical pharmacy services in United States hospitals in 2020: services and staffing. Pharmacotherapy. 2004; 24:427-40.
73. Iezzoni LI. Assessing quality using administrative data. Ann Intern Med. 1997; 127:666-74.